Controlled systemic delivery of indomethacin using membrane-moderated, cream formulation-based transdermal devices.
The present study was carried out to design a viable and practically effective transdermal systems of indomethacin using cream-based drug reservoirs and suitable rate controlling membranes. As vehicles, a more lipophilic base (F(1)) and a cream formulation containing predominant aqueous phase (F(2)) were chosen to study the influence of vehicle nature and role of permeation enhancers that increases thermodynamic activity and to provide diffusible species of drug to skin. Rate controlling membranes of cellulose acetate (CA) and ethyl cellulose (EC) with polyvinyl pyrollidine and hydroxypropyl methyl cellulose were used to design transdermal devices. In vivo, effective plasma concentrations of indomethacin are maintained up to 24 hr whereas oral formulation showed only up to 8 hr. Although the plasma drug levels between both EC films differ insignificantly, PVP film showed a better pharmacokinetic profile. The pharmacodynamic performance of the transdermal devices exhibited good anti-inflammatory activity over 24 hr compared with orally administered indomethacin. In vivo studies indicate the superiority of CA films over the EC films. Further, enhancement may be achieved with other classic enhancers/enhancement strategies with such devices containing aqueous cream vehicle and the optimum membranes.
Eminent Services Corporation, Frederick, Maryland, USA.
P Rama
PR
Rao
Kishore B
KB
Chalasani
Abhay S
AS
Chauhan
Akhlesh K
AK
Jain
Prakash V
PV
Diwan
Meduri Kodanda
MK
Ram
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D019540:Area Under Curve; D002482:Cellulose / Q000031:analogs & derivatives / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D004655:Emulsions / Q000737:chemistry; D065347:Hypromellose Derivatives; D066298:In Vitro Techniques; D007213:Indomethacin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008297:Male; D008567:Membranes, Artificial; D008747:Methylcellulose / Q000031:analogs & derivatives / Q000737:chemistry; D011145:Polyvinyls / Q000737:chemistry; D011759:Pyrrolidines / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D012867:Skin / Q000378:metabolism; D012869:Skin Absorption; D013276:Stomach Ulcer / Q000139:chemically induced
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D004655:Emulsions; D008567:Membranes, Artificial; D011145:Polyvinyls; D011759:Pyrrolidines; C505150:poly(N-vinylpyrrolidine); C005062:acetylcellulose; D065347:Hypromellose Derivatives; C013517:ethyl cellulose; D002482:Cellulose; D008747:Methylcellulose; D007213:Indomethacin